Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Atrovent Nasal Spray in Pediatric Patients with Rhinorrhea
NCT02238210Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2002
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of ipratropium bromide in common cold, allergic rhinitis (AR), sponsored by Boehringer Ingelheim. Started Dec 2002; status: completed.
02
Drugs
ipratropium bromide
03
Conditions
common coldallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02238210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238210.